ArticleFrontiers in endocrinology2026
MRI characteristics of cervical radioiodine-avid lymph nodes detected on post-therapeutic ¹³¹I whole-body scintigraphy in differentiated thyroid carcinoma.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to characterize the magnetic resonance imaging (MRI) features of cervical metastatic lymph nodes in differentiated thyroid carcinoma (DTC) and provide imaging-based evidence for identifying metastatic cervical lymph nodes prior to administration of radioactive iodine (¹³¹I) therapy. Methods: Clinical and imaging data from 32 patients with histologically confirmed DTC who underwent ¹³¹I therapy at Haikou People's Hospital between June 2019 and May 2024 were retrospectively analyzed. All patients demonstrated cervical radioiodine-avid lymph nodes on post-therapeutic ¹³¹I whole-body scintigraphy (¹³¹I-Rx-WBS). Cervical ultrasonography (US) and MRI examinations were conducted prior to Results: All participants were diagnosed with papillary thyroid carcinoma. The median age was 45.5 years (range, 28-66 years). Cervical US detected lymph node metastasis in 15.6% (5/32) of cases. A total of 58 radioiodine-avid lymph nodes were identified across cervical levels II-VI and the supraclavicular region. MRI analysis demonstrated that most radioiodine-avid lymph nodes exhibited hyperintensity on T Conclusion: Cervical lymph nodes demonstrating radioiodine uptake on ¹³¹I-Rx-WBS frequently present with round to ovoid or irregular morphology and indistinct margins on MRI. However, given the high density of cervical lymph nodes and overlapping imaging characteristics between radioiodine-avid and radioiodine-negative nodes, a comprehensive assessment integrating multimodal imaging and clinical correlation is essential for accurate assessment before ¹³¹I therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.